Non-Insulin Therapies for Diabetes Market is expected to witness robust growth with Eli Lily and Company receiving the U.S. FDA approval for its Trijardy XR medicine, indicated for type-2 diabetes.
Non-Insulin Reactions can be managed by taking a well-balanced diet, exercising regularly, and avoiding foods that contain excessive amounts of sugar. It has also been discovered that some individuals suffer from this condition due to a lack of digestive enzymes. There are many different alternative approaches that can be used to manage this condition including the use of dietary supplements, the administration of oral or intravenous medications, and physical therapies. Increasing prevalence of diabetes is expected to drive growth of the global non-insulin therapies for diabetes market . According to the World Health Organization (WHO), the global prevalence of diabetes among adults aged 18 years and above increased from 4.7% in 1980 to 8.5% in 2014. According to the same source, in 2016, around 1.6 million deaths across the globe were associated with diabetes. Furthermore, according to the International Diabetes Federation (IDF), in 2019, around 374 million people were ...